Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples

CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.

The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.

Potential Commercial Applications:		Competitive Advantages:
Clinical monitoring of individual patient antiretroviral therapy HIV/AIDS public health programs Surveillance of retroviral drug resistance Screening of blood donations		Rapid diagnostic which greatly reduces time and labor for improved clinical monitoring of HIV treatment Ready for commercialization Easily adapted to kit format Assists continued usefulness of common antiretroviral therapeutics Useful for high-throughput serum samples screening

Development Stage:
In vitro data available

Related Invention(s):
E-129-2013-0
E-129-2013-1


Inventors:

Walid Heneine (CDC)  ➽ more inventions...

Thomas Folks (CDC)  ➽ more inventions...

Shinji Yamamoto (CDC)  ➽ more inventions...

William Switzer (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 5,849,494 issued 1998-12-15
U.S. Pat: 6,136,534 issued 2000-10-24
US Application No. 09/123,012
US Application No. 08/379,851
Various international patents issued or pending

Publications:
Yamamoto S, et al. PMID 8882946
Heneine W, et al. PMID 7538549
Reisler RB, et al. PMID 11176273

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-232-1993-0
Updated: Jan 27, 2014